GB9621757D0 - Phenyl-substituted bicyclic heterocyclyl derivatives and their use - Google Patents

Phenyl-substituted bicyclic heterocyclyl derivatives and their use

Info

Publication number
GB9621757D0
GB9621757D0 GBGB9621757.5A GB9621757A GB9621757D0 GB 9621757 D0 GB9621757 D0 GB 9621757D0 GB 9621757 A GB9621757 A GB 9621757A GB 9621757 D0 GB9621757 D0 GB 9621757D0
Authority
GB
United Kingdom
Prior art keywords
phenyl
bicyclic heterocyclyl
substituted bicyclic
heterocyclyl derivatives
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9621757.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Priority to GBGB9621757.5A priority Critical patent/GB9621757D0/en
Publication of GB9621757D0 publication Critical patent/GB9621757D0/en
Priority to PCT/EP1997/005697 priority patent/WO1998017662A1/en
Priority to AU49479/97A priority patent/AU4947997A/en
Pending legal-status Critical Current

Links

GBGB9621757.5A 1996-10-18 1996-10-18 Phenyl-substituted bicyclic heterocyclyl derivatives and their use Pending GB9621757D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9621757.5A GB9621757D0 (en) 1996-10-18 1996-10-18 Phenyl-substituted bicyclic heterocyclyl derivatives and their use
PCT/EP1997/005697 WO1998017662A1 (en) 1996-10-18 1997-10-16 Phenyl-substituted bicyclic heterocyclyl derivatives and their use
AU49479/97A AU4947997A (en) 1996-10-18 1997-10-16 Phenyl-substituted bicyclic heterocyclyl derivatives and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9621757.5A GB9621757D0 (en) 1996-10-18 1996-10-18 Phenyl-substituted bicyclic heterocyclyl derivatives and their use

Publications (1)

Publication Number Publication Date
GB9621757D0 true GB9621757D0 (en) 1996-12-11

Family

ID=10801645

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9621757.5A Pending GB9621757D0 (en) 1996-10-18 1996-10-18 Phenyl-substituted bicyclic heterocyclyl derivatives and their use

Country Status (3)

Country Link
AU (1) AU4947997A (en)
GB (1) GB9621757D0 (en)
WO (1) WO1998017662A1 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1445A (en) 1997-10-27 2005-07-10 Agouron Pharma Substituted 4-amino-thiazol-2-yl compounds as CDKs inhibitors.
FR2781154B1 (en) * 1998-07-15 2001-09-07 Lafon Labor THERAPEUTIC COMPOSITION BASED ON ISOFLAVONOIDS FOR USE IN THE TREATMENT OF TUMORS WITH CYTOTOXIC AGENTS
FR2797444B1 (en) * 1999-08-13 2003-02-07 Lafon Labor PHARMACEUTICAL COMPOSITIONS COMPRISING 4-QUINOLONES
YU54202A (en) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
HN2001000008A (en) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals AMIDA COMPOSITE AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES, AND THE INSTRUCTIONS FOR USE
JP2004501083A (en) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド Pyrazole for inhibiting protein kinases
KR100399364B1 (en) * 2000-09-18 2003-09-26 주식회사 엘지생명과학 3-Hydroxy-6-aminochromene-4-on derivatives useful as cyclin dependendent kinase inhibitors
EP1280789A1 (en) 2000-05-03 2003-02-05 LG Life Sciences Ltd. Cdk inhibitors having 3-hydroxychromen-4-one structure
CA2411928A1 (en) 2000-08-09 2002-02-14 Agouron Pharmaceuticals, Inc. Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclindependent kinases
JP2004506720A (en) 2000-08-18 2004-03-04 アグーロン　ファーマシューティカルズ，インコーポレイテッド Heterocyclic hydroxyiminofluorenes and their use for protein kinase inhibition
FR2813791B1 (en) * 2000-09-14 2004-03-12 Lafon Labor USE OF 2- AND 4-QUINOLONES TO INHIBIT INTIMAL NEO-PROLIFERATION
GB0030729D0 (en) * 2000-12-16 2001-01-31 Univ Nottingham Substituted-4-Quinolones
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
AU2003265737B2 (en) * 2002-10-02 2008-10-16 Novogen Research Pty Ltd Combination chemotherapy compositions and methods
CN100378105C (en) * 2003-01-31 2008-04-02 中国人民解放军***联勤部军事医学研究所 Pyran isoflavone molluscacide synthesizing method and formulation
AU2004230841A1 (en) * 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7601855B2 (en) 2004-09-21 2009-10-13 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
EP1856083A4 (en) * 2005-03-11 2009-05-27 Univ Michigan Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
EP1886996A1 (en) * 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
KR20090035744A (en) * 2006-08-10 2009-04-10 페레르 인터내쇼날 에스.에이. 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
WO2009026657A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Flavonoid ppar agonists
WO2010054264A1 (en) 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
CN102238951A (en) * 2008-12-05 2011-11-09 大塚制药株式会社 Pharmaceutical agent comprising quinolone compound
TWI472525B (en) 2008-12-05 2015-02-11 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519170A (en) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー INSITU method for monitoring EMT status of tumor cells in vivo
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012520893A (en) 2009-03-18 2012-09-10 オーエスアイ・ファーマシューティカルズ，エルエルシー Combination cancer treatment comprising administration of an EGFR inhibitor and an IGF-1R inhibitor
JP2013510564A (en) 2009-11-13 2013-03-28 パンガエア ビオテック、ソシエダッド、リミターダ Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
CA2816322A1 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compositions and methods for the treatment of cancer
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US20130084286A1 (en) 2011-08-31 2013-04-04 Thomas E. Januario Diagnostic markers
EP2761025A1 (en) 2011-09-30 2014-08-06 Genentech, Inc. Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
CN105017145B (en) * 2012-12-12 2017-12-05 王子厚 7-chloro-4-oxo-quinoline derivative with antitumor activity
CA2941010A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
EP2976085A1 (en) 2013-03-21 2016-01-27 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
CA2923667A1 (en) 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Cancer therapy
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
KR20170095893A (en) 2014-12-24 2017-08-23 제넨테크, 인크. Therapeutic, diagnostic, and prognostic methods for cancer of the bladder
MX2017010002A (en) 2015-02-02 2018-02-09 Mei Pharma Inc Combination therapies.
SG11201906223TA (en) 2016-12-22 2019-08-27 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
JP7361722B2 (en) 2018-05-04 2023-10-16 アムジエン・インコーポレーテツド KRAS G12C inhibitors and methods of using the same
MA52501A (en) 2018-05-04 2021-03-10 Amgen Inc KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
MX2020012261A (en) 2018-06-12 2021-03-31 Amgen Inc Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer.
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
JP2020090482A (en) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Improved synthesis of key intermediate of kras g12c inhibitor compound
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2021007104A (en) 2018-12-20 2021-08-11 Amgen Inc Kif18a inhibitors.
MA54546A (en) 2018-12-20 2022-03-30 Amgen Inc HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
EP3898592A1 (en) 2018-12-20 2021-10-27 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
CA3123871A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
US20230148450A9 (en) 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CN113727758A (en) 2019-03-01 2021-11-30 锐新医药公司 Bicyclic heterocyclic compounds and use thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
US11236091B2 (en) 2019-05-21 2022-02-01 Amgen Inc. Solid state forms
JP2022542967A (en) 2019-08-02 2022-10-07 アムジエン・インコーポレーテツド KIF18A inhibitor
MX2022001296A (en) 2019-08-02 2022-02-22 Amgen Inc Kif18a inhibitors.
JP2022542394A (en) 2019-08-02 2022-10-03 アムジエン・インコーポレーテツド Heteroarylamides useful as KIF18A inhibitors
CN114391012A (en) 2019-08-02 2022-04-22 美国安进公司 Pyridine derivatives as KIF18A inhibitors
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
KR20220109407A (en) 2019-11-04 2022-08-04 레볼루션 메디슨즈, 인크. RAS inhibitors
PE20221278A1 (en) 2019-11-04 2022-09-05 Revolution Medicines Inc RAS INHIBITORS
BR112022008534A2 (en) 2019-11-04 2022-08-09 Revolution Medicines Inc COMPOUNDS, PHARMACEUTICAL COMPOSITION, CONJUGATE AND METHODS TO TREAT CANCER AND TO TREAT A RAS PROTEIN-RELATED DISORDER
CR20220200A (en) 2019-11-08 2022-07-28 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof
BR112022009390A2 (en) 2019-11-14 2022-08-09 Amgen Inc IMPROVED SYNTHESIS OF KRAS INHIBITOR COMPOUND G12C
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
CN114980976A (en) 2019-11-27 2022-08-30 锐新医药公司 Covalent RAS inhibitors and uses thereof
CA3163703A1 (en) 2020-01-07 2021-07-15 Steve Kelsey Shp2 inhibitor dosing and methods of treating cancer
EP4168002A1 (en) 2020-06-18 2023-04-26 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
WO2022140427A1 (en) 2020-12-22 2022-06-30 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
AU2022270116A1 (en) 2021-05-05 2023-12-21 Revolution Medicines, Inc. Ras inhibitors
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CN117616031A (en) 2021-05-05 2024-02-27 锐新医药公司 RAS inhibitors for the treatment of cancer
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE666541A (en) * 1964-07-08
GB1495189A (en) * 1975-09-12 1977-12-14 Pfizer Ltd 4-oxo-4h-benzopyran derivatives and process for their preparation
FR2693724B1 (en) * 1992-07-17 1994-10-07 Lipha Use of benzopyran or benzothiopyran compounds for the induction of the expression of genes for the nodulation of bacteria of the genus Rhizobium associated with legumes.
US5741476A (en) * 1992-12-21 1998-04-21 Mallinckrodt Medical, Inc. Polyhydric phenol compounds
WO1996035683A1 (en) * 1995-05-09 1996-11-14 Nippon Kayaku Kabushiki Kaisha Novel physiologically active na23063 analogues, process for producing the same and use of the same

Also Published As

Publication number Publication date
AU4947997A (en) 1998-05-15
WO1998017662A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
GB9621757D0 (en) Phenyl-substituted bicyclic heterocyclyl derivatives and their use
GB2324672B (en) Vision system and proximity detector
ZA9710339B (en) Xanthines and their therapeutic use
ZA9711141B (en) Novel ketobenzamides and their use
HK1007865A1 (en) Sulphonamides and their use
IL120124A0 (en) Heteroaryl-oxazolidinones their preparation and use
HK1005801A1 (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
HUP9902463A3 (en) Fixture and prosthesis including the same
EP0894807A4 (en) GPIb-LIPID COMPLEX AND USES THEREOF
ZA975591B (en) New amidino derivatives and their use as thrombininhibitors
HRP970225A2 (en) Benzofuryl derivatives and their use
AU1886197A (en) Quinolones and their therapeutic use
IL126476A0 (en) Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents
GB9625899D0 (en) Substances and their uses
GB2304309B (en) Laminate and use thereof
HUP9700446A3 (en) Oilsuspension-concentrate and using thereof
ZA974830B (en) Triazine derivatives and their use
ZA978876B (en) Oxazolone derivatives and their use
PL331523A1 (en) Azolotrizines and azolopyrimidines
AU3116697A (en) Human interleukin-1j and antagonists thereof
IL123535A0 (en) Benzoxazindione derivatives and their use
HUP0001792A3 (en) Dibenzo-oxazepine and-dioxepine derivatives and their use as anti-tumor agents
AU3935897A (en) B1-bradykinin receptor antagonists and use thereof
EP0744125A3 (en) Iodo-complex and its use
HUP9900068A3 (en) Fuse-switch and/or fuse-disconnector